Progeria-short stature-pigmented nevi syndrome

Progeria-short stature-pigmented nevi syndrome, also known as Mulvihill-Smith syndrome, is an extremely rare genetic disorder characterized by features of premature aging (progeria), markedly short stature, and multiple pigmented nevi (moles) on the skin. The condition was first described by Mulvihill and Smith in 1975. Affected individuals typically present with intrauterine growth retardation, microcephaly (small head), a distinctive facial appearance with a small triangular face, and a high-pitched voice. Additional features may include sensorineural hearing loss, immunodeficiency with recurrent respiratory infections, and reduced subcutaneous fat. The skin is notably affected, with numerous pigmented nevi appearing progressively, and patients may also develop signs of premature aging such as thin or sparse hair and aged-appearing skin. Cognitive development is generally preserved, though some degree of intellectual disability has been reported in certain cases. The syndrome affects multiple body systems including the integumentary (skin), immune, skeletal, and sensory systems. Immunological abnormalities, particularly involving T-cell function, contribute to increased susceptibility to infections. Some patients have been reported to develop tumors, suggesting a possible predisposition to neoplasia. The condition has been associated with mutations in the NSMCE3 gene (also known as NDNL2), which plays a role in DNA repair. Given the extreme rarity of this condition, there is no specific treatment available. Management is supportive and symptomatic, focusing on monitoring growth, addressing hearing loss with appropriate aids, managing infections related to immunodeficiency, and surveillance for potential malignancies. Regular dermatological monitoring of pigmented nevi is also recommended.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Progeria-short stature-pigmented nevi syndrome